Sutinat 50 mg (Sunitinib)
| Active Ingredient | Sunitinib |
|---|---|
| Indication: | Kidney Cancer and Gastrointestinal Stromal Tumor |
| Manufacturer: | Natco Pharma Ltd. |
| Packaging | 28 capsules in 1 bottle |
| Strength | 50mg |
| Delivery Time | 6 To 15 days |
Sutinat 50 mg contains Sunitinib, a targeted cancer therapy known as a tyrosine kinase inhibitor (TKI). It is primarily used in the treatment of advanced renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors. Sunitinib works by blocking specific enzymes that promote cancer cell growth, division, and blood supply.
Sutinat 50 mg is prescribed under strict oncological supervision and is typically taken in treatment cycles (e.g., 4 weeks on, 2 weeks off). It offers targeted action with fewer effects on healthy cells compared to traditional chemotherapy. Regular monitoring is essential during therapy to manage side effects and evaluate response.








There are no reviews yet.